References
- Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39(Suppl 1): 7–18.
- Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma–review. Front Oncol. 2021; 11:776863. doi: 10.3389/fonc.2021.776863
- Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: a SEER population-based cohort study. Cancer Med. 2022; 11:692–704.
- Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7
- Jin W. ErBb family proteins in cholangiocarcinoma and clinical implications. J Clin Med. 2020; 9:2255. doi: 10.3390/jcm9072255
- Mancinelli R, Mammola CL, Sferra R, Pompili S, Vetuschi A, Pannarale L. Role of the angiogenic factors in cholangiocarcinoma. Appl Sci. 2019; 9:1393. doi: 10.3390/app9071393
- Ma Z, Li H, Liu L. Combining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literature. Recent Pat Anticancer Drug Discov. 2021; 16:101–7.
- Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019; 70:700–9.
- Liao W, Feng Q, Liu H, Du J, Chen X, Zeng Y. Circular RNAs in cholangiocarcinoma. Cancer Lett. 2022; 553:215980. doi: 10.1016/j.canlet.2022.215980
- Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021; 27:100354. doi: 10.1016/j.ctarc.2021.100354
- Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery. World J Surg. 2018; 42:1848–56.
- Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 2019; 14:e0220527. doi: 10.1371/journal.pone.0220527
- Sarkis Y, Al Soueidy A, Kourie HR. Will advanced cholangiocarcinoma become a targetable malignancy? Crit Rev Oncol Hematol. 2021; 159:103233. doi: 10.1016/j.critrevonc.2021.103233
- Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7
- Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020; 11:573. doi: 10.1038/s41419-020-02749-7
- Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NFκB pathway activation. Int J Oncol. 2020; 56:101–12.
- Takaya A, Yamamoto T, Tokoyoda K. Humoral immunity vs. Salmonella. Front Immunol. 2020; 10: 3155. doi: 10.3389/fimmu.2019.03155
- Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M, Hoffman RM. Efficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine models. Cells. 2019; 8:599. doi: 10.3390/cells8060599
- Zhao T, Guo M, Chen H, Zhou L, Guo J, Liu S, et al. IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth. Curr Mol Pharmacol. 2023; 16:881–93.
- Phan T, Nguyen VH, D’Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, et al. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 2020; 27: 235–45.